Inmunobiogram Transplants2018-11-08T09:52:29+00:00


Inmunobiogram® is being studied in Renal Transplantation under a comprehensive clinical plan program, which includes a first clinical study in 70 patients (BH-Pilot) and an international validation study in 200 patients (TRANSBIO clinical study).

“BH-Pilot” was a clinical study performed in 2017 in “La Paz” and “Puerta de Hierro” University Hospitals (Madrid). An interim analysis showing a positive proof of concept was presented at an investigator meeting with our Scientific Advisory Board held in the context of the European Society of Organ Transplantation (Barcelona, 24-27 September 2017).

La foto llevará un pie de foto que

clic to know R&D Pipelines

Final results coming from 70 patients indicate that:

  • The INMUNOBIOGRAM® provides an individualized patient response pattern to immunosuppressive medication.

  • Sensitivity ranges can be determined in each patient for each of the drugs tested.

  • Significantly associated low-sensitivity patterns have been observed in patients who present worse clinical evolution and also receive higher doses of medication. These low-sensitivity patterns actually are more prominent to those drugs that patients are currently taking. On the contrary, patients with a low-risk profile show better

Final results from “BH-Pilot” were presented this year at the 27th International Congress of the Transplantation Society, TTS2018 (3rd of July Madrid).

TRANSBIO clinical study is an international (European and USA) and multicenter trial, to evaluate the clinical consistency and analytical robustness of Inmunobiogram® as an In Vitro Diagnostics BIOtechnological Tool to help decision-making in the adjustment of immunosuppressant therapy for Renal TRANSplant. Transbio study began in May 2018 and it is expected to give conclusive results in 2019.

“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement Nº 733248”

“This information reflects only Biohope’s view; the Agency is not responsible for any use that may be made of the information it contains herein”.